Barclays upgrades Givaudan stock to Buy at CHF 3,850.00

Published on 10/07/2026 at 09:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Givaudan stock costs EUR 3,654.00 on October 7, 2026 after EUR 3,620.00. Quarterly revenue was CHF 3.80 billion, up 97.00 percent.

A soft watercolour painting of a vast lavender field in full bloom. Neat violet rows stretch to the horizon where snow-capped Swiss Alpine peaks rise in muted blue-grey silhouette. The sky is painted in gentle washes of peach and pale blue. Loose wet-on-w — Givaudan CH0010645932 Aquarell eines Lavendelfeldes vor stiller Schweizer Alpen-Silhouette in zarten Pastelltönen, Illustration mit AI erstellt.

Givaudan S.A. (ISIN CH0010645932) was trading at EUR 3,654.00 at Lang & Schwarz on October 7, 2026 at 9:23 a.m. CEST, up EUR 34.00 or 0.94 percent versus the prior close of EUR 3,620.00. The latest catalyst is Barclays' October 5 upgrade of Givaudan to Buy with a CHF 3,850.00 price target, according to Yahoo Finance.

Barclays sees recovery potential

The Barclays call raised the rating from Equal Weight to Overweight and lifted the target by 12 percent to CHF 3,850.00, citing better growth prospects in Taste & Wellbeing. The same report raised the group's organic growth forecast to 5.80 percent from 5.00 percent and adjusted EBITDA to CHF 2.02 billion, according to Yahoo Finance.

The forecast rests on a recovery rather than a clean earnings acceleration. Taste & Wellbeing organic sales growth slowed to 1.50 percent in the second quarter, while Health & Functional sales were forecast to fall 15.00 percent. Raw-material inflation and weaker luxury beauty demand remain the quantified risks cited in the report.

June quarter shows the pressure

For the quarter ending June 30, 2026, Givaudan reported revenue of CHF 3.80 billion and net income of CHF 475.00 million. The comparable figures cited for the prior year were CHF 1.93 billion of revenue and CHF 296.00 million of net income, according to Markets Insider.

Givaudan's investor page lists fiscal year 2025 sales of CHF 7.47 billion, like-for-like sales growth of 5.10 percent, EBITDA of CHF 1.75 billion and net income of CHF 1.07 billion. Those full-year figures provide a larger base, but the June-quarter comparison keeps the near-term debate centered on margins and divisional recovery.

Results date gives the next test

Givaudan is scheduled to report third-quarter results on October 13, 2026, according to Yahoo Finance. For the stock, that date matters because the current valuation debate depends on whether Taste & Wellbeing can move from 1.50 percent organic growth in the second quarter toward the 5.80 percent group forecast.

Givaudan stock stays near yearly high

At 9:23 a.m. CEST on October 7, 2026, Givaudan was trading at EUR 3,654.00 at Lang & Schwarz, plus 0.94 percent versus the EUR 3,620.00 prior close dated October 6, 2026. Its primary listing is on SIX in Swiss francs, where the finance quote showed CHF 3,410.00 at 7:13 a.m. UTC on October 7, 2026, with a market capitalization of CHF 31.5 billion and a 52-week range of CHF 2,566.00 to CHF 3,592.00. The further course of trading is shown by the continuously updated real-time quote of Givaudan stock.